← Back to Search

Anti-androgen

VDPHL01 for Male Pattern Baldness

Phase 2
Recruiting
Research Sponsored by Veradermics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is male aged 18-60 years old
Subject has a clinical diagnosis of mild to moderate AGA
Must not have
Subject has been diagnosed with COVID-19 within 16 weeks of baseline
Subject has uncontrolled blood pressure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 6
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety and effectiveness of VDPHL01 in men with male pattern baldness. Male pattern baldness is a genetic condition where hair follicles are overly sensitive to hormones, leading

Who is the study for?
This trial is for men with Androgenetic Alopecia, commonly known as male pattern baldness. Participants should be genetically predisposed to hair loss due to a high sensitivity of hair follicles to hormones. The study requires regular visits over 6 months.
What is being tested?
The trial is testing VDPHL01, an investigational oral tablet intended to treat male pattern baldness by being taken twice daily. It's designed to see if the drug is safe and effective in stopping or reversing hair loss in men.
What are the potential side effects?
Since this summary does not provide specific side effects of VDPHL01, it can only be noted that potential side effects will be monitored throughout the study's multiple visits.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man between 18 and 60 years old.
Select...
I have been diagnosed with mild to moderate age-related hair loss.
Select...
I am in good health with normal kidney and liver function.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I was diagnosed with COVID-19 within the last 16 weeks.
Select...
My blood pressure is not under control.
Select...
I have a history of heart or thyroid issues.
Select...
I have a history of heart or thyroid disease.
Select...
I have received an organ transplant.
Select...
I have had radiation treatment on my scalp.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in non-vellus Total Area Hair Count (TAHC)
Subjects Evaluation of Treatment Benefit

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VDPHL01 TabletExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Veradermics, Inc.Lead Sponsor
2 Previous Clinical Trials
630 Total Patients Enrolled
~12 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top